Abstract:Background: Acute myeloid leukemia (AML) is the most common form of leukemia among adults and is characterized by uncontrolled proliferation and clonal expansion of hematopoietic cells. There has been a significant improvement in the treatment of younger patients, however, prognosis in the elderly AML patients remains poor. Methods: We used computational methods and machine learning (ML) techniques to identify and explore the differential high-risk genes (DHRGs) in AML. The DHRGs were explored through multiple in silico approaches including genomic and functional analysis, survival analysis, immune infiltration, miRNA co-expression and stemness features analyses to reveal their prognostic importance in AML. Furthermore, using different ML algorithms, prognostic models were constructed and validated using the DHRGs. At the end molecular docking studies were performed to identify potential drug candidates targeting the selected DHRGs. Results: We identified a total of 80 DHRGs by comparing the differentially expressed genes derived between AML patients and normal controls and high-risk AML genes identified by Cox regression. Genetic and epigenetic alteration analyses of the DHRGs revealed a significant association of their copy number variations and methylation status with overall survival (OS) of AML patients. Out of the 137 models constructed using different ML algorithms, the combination of Ridge and plsRcox maintained the highest mean C-index and was used to build the final model. When AML patients were classified into low- and high-risk groups based on DHRGs, the low-risk group had significantly longer OS in the AML training and validation cohorts. Furthermore, immune infiltration, miRNA coexpression, stemness feature and hallmark pathway analyses revealed significant differences in the prognosis of the low- and high-risk AML groups. Drug sensitivity and molecular docking studies revealed top 5 drugs, including carboplatin and austocystin-D that may significantly affect the DHRGs in AML. Conclusion: The findings from the current study identified a set of high-risk genes that may be used as prognostic and therapeutic markers for AML patients. In addition, significant use of the ML algorithms in constructing and validating the prognostic models in AML was demonstrated. Although our study used extensive bioinformatics and machine learning methods to identify the hub genes in AML, their experimental validations using knock-out/-in methods would strengthen our findings.

Identification of crucial genes and prediction of small molecules for multidrug resistance of Hodgkin's lymphomas.

[Identification of Multidrug Resistance Related Genes in Leukemia by Suppression Subtractive Hybridization].

Identification and validation of differentially expressed genes for targeted therapy in NSCLC using integrated bioinformatics analysis

Identification of Candidate Biomarkers Correlated With the Pathogenesis and Prognosis of Non-small Cell Lung Cancer via Integrated Bioinformatics Analysis

Identification of a Novel Gene Signature and Potential Mechanisms Related to Targeted Drug Resistance in Hepatocellular Carcinoma Based on Integrating Bioinformatics and Machine Learning

Survival prediction and analysis of drug-resistance genes in HER2-positive breast cancer

Identification of hub genes and small molecule therapeutic drugs related to breast cancer with comprehensive bioinformatics analysis

Identification of Hub Genes and Small Molecule Drugs Associated with Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer

Discovery of new drug therapeutic indications from gene mutation information for hepatocellular carcinoma

Differential Regulatory Network-Based Quantification and Prioritization of Key Genes Underlying Cancer Drug Resistance Based on Time-Course RNA-seq Data.

Prediction of Novel Drugs for Hepatocellular Carcinoma Based on Multi-Source Random Walk

Integrative analysis of blood transcriptome profiles in small-cell lung cancer patients for identification of novel chemotherapy resistance-related biomarkers

Identification of Potential Drugs for Diffuse Large B-Cell Lymphoma Based on Bioinformatics and Connectivity Map Database.

Insights into the Gene Expression Profile of Classical Hodgkin Lymphoma: A Study towards Discovery of Novel Therapeutic Targets

Identification of critical genes associated with radiotherapy resistance in cervical cancer by bioinformatics

Predict New Therapeutic Drugs for Hepatocellular Carcinoma Based on Gene Mutation and Expression.

Identification of hub genes and potential molecular mechanisms related to drug sensitivity in acute myeloid leukemia based on machine learning

Identification and characterization of biomarkers and their functions for Lapatinib-resistant breast cancer

Identification of Potential Crucial Genes and Key Pathways in Breast Cancer Using Bioinformatic Analysis

Predicting Therapeutic Drugs for Hepatocellular Carcinoma Based on Tissue-Specific Pathways

Screening and Identification of Genes Associated with Multi-Drug Resistance in Colonic Cancer